Development of a predictive score for potentially avoidable hospital readmissions for general internal medicine patients.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 11 09 2018
accepted: 21 06 2019
entrez: 16 7 2019
pubmed: 16 7 2019
medline: 10 3 2020
Statut: epublish

Résumé

Identifying patients at high risk of hospital preventable readmission is an essential step towards selecting those who might benefit from specific transitional interventions. Derive and validate a predictive risk score for potentially avoidable readmission (PAR) based on analysis of readmissions, with a focus on medication. Retrospective analysis of all hospital admissions to internal medicine wards between 2011 and 2014. Comparison between patients readmitted within 30 days and non-readmitted patients, as identified using a specially designed algorithm. Univariate and multivariate regression analyses of demographic data, clinical diagnoses, laboratory results, and the medication data of patients admitted during the first period (2011-2013), to identify factors associated with PAR. Using these, derive a predictive score with a regression coefficient-based scoring method. Subsequently, validate this score with a second cohort of patients admitted in 2013-2014. Variables were identified at hospital discharge. The derivation cohort included 7,317 hospital stays. Multivariate logistic regressions found significant associations with PAR for: [adjusted OR (95% CI)] hospital length of stay > 4 days [1.3 (1.1-1.7)], admission in previous 6 months [2.3 (1.9-2.8)], heart failure [1.3 (1.0-1.7)], chronic ischemic heart disease [1.7 (1.2-2.3)], diabetes with organ damage [2.2 (1.3-3.8)], cancer [1.4 (1.0-1.9)], metastatic carcinoma [1.9 (1.3-3.0)], anemia [1.2 (1.0-1.5)], hypertension [1.3 (1.1-1.7)], arrhythmia [1.3 (1.0-1.6)], hyperkalemia [1.4 (1.0-1.7)], opioid drug prescription [1.3 (1.1-1.6)], and acute myocardial infarction [0.6 (0.4-0.9)]. The PAR-Risk Score, derived from these results, demonstrated fair discriminatory and calibration power (C-statistic = 0.699; Brier Score = 0.069). The results for the validation cohort's operating characteristics were similar (C-statistic = 0.687; Brier Score = 0.064). This study identified routinely-available factors that were significantly associated with PAR. A predictive score was derived and internally validated.

Sections du résumé

BACKGROUND
Identifying patients at high risk of hospital preventable readmission is an essential step towards selecting those who might benefit from specific transitional interventions.
OBJECTIVE
Derive and validate a predictive risk score for potentially avoidable readmission (PAR) based on analysis of readmissions, with a focus on medication.
DESIGN/SETTING/PARTICIPANTS
Retrospective analysis of all hospital admissions to internal medicine wards between 2011 and 2014. Comparison between patients readmitted within 30 days and non-readmitted patients, as identified using a specially designed algorithm. Univariate and multivariate regression analyses of demographic data, clinical diagnoses, laboratory results, and the medication data of patients admitted during the first period (2011-2013), to identify factors associated with PAR. Using these, derive a predictive score with a regression coefficient-based scoring method. Subsequently, validate this score with a second cohort of patients admitted in 2013-2014. Variables were identified at hospital discharge.
RESULTS
The derivation cohort included 7,317 hospital stays. Multivariate logistic regressions found significant associations with PAR for: [adjusted OR (95% CI)] hospital length of stay > 4 days [1.3 (1.1-1.7)], admission in previous 6 months [2.3 (1.9-2.8)], heart failure [1.3 (1.0-1.7)], chronic ischemic heart disease [1.7 (1.2-2.3)], diabetes with organ damage [2.2 (1.3-3.8)], cancer [1.4 (1.0-1.9)], metastatic carcinoma [1.9 (1.3-3.0)], anemia [1.2 (1.0-1.5)], hypertension [1.3 (1.1-1.7)], arrhythmia [1.3 (1.0-1.6)], hyperkalemia [1.4 (1.0-1.7)], opioid drug prescription [1.3 (1.1-1.6)], and acute myocardial infarction [0.6 (0.4-0.9)]. The PAR-Risk Score, derived from these results, demonstrated fair discriminatory and calibration power (C-statistic = 0.699; Brier Score = 0.069). The results for the validation cohort's operating characteristics were similar (C-statistic = 0.687; Brier Score = 0.064).
CONCLUSION
This study identified routinely-available factors that were significantly associated with PAR. A predictive score was derived and internally validated.

Identifiants

pubmed: 31306461
doi: 10.1371/journal.pone.0219348
pii: PONE-D-18-26595
pmc: PMC6629067
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0219348

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ann Intern Med. 2012 Sep 18;157(6):417-28
pubmed: 22986379
Med Care. 2006 Nov;44(11):972-81
pubmed: 17063128
J Hosp Med. 2011 Feb;6(2):54-60
pubmed: 20945293
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur Heart J. 2006 Oct;27(19):2285-93
pubmed: 16908490
N Engl J Med. 2016 Apr 21;374(16):1543-51
pubmed: 26910198
Annu Rev Med. 2014;65:471-85
pubmed: 24160939
Eur J Intern Med. 2012 Jul;23(5):451-6
pubmed: 22726375
Ann Intern Med. 2003 Feb 4;138(3):161-7
pubmed: 12558354
JAMA. 2011 Oct 19;306(15):1688-98
pubmed: 22009101
J Clin Epidemiol. 2002 Jun;55(6):573-87
pubmed: 12063099
JAMA. 2016 Nov 22;316(20):2115-2125
pubmed: 27893129
BMC Med Inform Decis Mak. 2014 Aug 04;14:65
pubmed: 25091637
Ann Intern Med. 2009 Feb 3;150(3):178-87
pubmed: 19189907
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
J Clin Nurs. 2006 May;15(5):599-606
pubmed: 16629969
J Am Geriatr Soc. 2013 Jan;61(1):113-21
pubmed: 23252914
CMAJ. 2010 Apr 6;182(6):551-7
pubmed: 20194559
J Gen Intern Med. 2005 Apr;20(4):317-23
pubmed: 15857487
Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):29-37
pubmed: 20031785
CMAJ. 2004 Feb 3;170(3):345-9
pubmed: 14757670
J Prev Med Public Health. 2012 Jul;45(4):259-66
pubmed: 22880158
Intern Med J. 2012 Jun;42(6):677-82
pubmed: 21790921
J Am Geriatr Soc. 2014 Jun;62(6):1116-21
pubmed: 24802165
Am J Health Syst Pharm. 2015 Feb 1;72(3):237-44
pubmed: 25596608
BMJ Open. 2015 Feb 18;5(2):e007259
pubmed: 25694461
BMC Health Serv Res. 2009 Jun 09;9:96
pubmed: 19505342
WMJ. 2012 Jun;111(3):119-23
pubmed: 22870557
BMJ. 2013 Dec 16;347:f7171
pubmed: 24342737
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
J Clin Epidemiol. 1999 Mar;52(3):171-9
pubmed: 10210233
Arch Intern Med. 2005 Sep 12;165(16):1842-7
pubmed: 16157827
CMAJ. 2011 Apr 19;183(7):E391-402
pubmed: 21444623
Swiss Med Wkly. 2016 Aug 06;146:w14335
pubmed: 27497141
Int J Qual Health Care. 2014 Jun;26(3):271-7
pubmed: 24737834
JAMA Intern Med. 2013 Apr 22;173(8):632-8
pubmed: 23529115
J Gen Intern Med. 2010 Mar;25(3):211-9
pubmed: 20013068
J Am Geriatr Soc. 2011 May;59(5):948-9
pubmed: 21568972
BMJ. 2015 Feb 05;350:h411
pubmed: 25656852
Eur J Intern Med. 2012 Jul;23(5):457-60
pubmed: 22726376
J Eval Clin Pract. 2017 Apr;23(2):391-401
pubmed: 27576302
N Engl J Med. 2009 Apr 2;360(14):1418-28
pubmed: 19339721
Ann Intern Med. 2011 Oct 18;155(8):520-8
pubmed: 22007045
Gerontologist. 1997 Dec;37(6):777-84
pubmed: 9432994

Auteurs

Anne-Laure Blanc (AL)

Pharmacy, Geneva University Hospitals, Geneva, Switzerland.
Pharmacie Interhospitalière de la Côte, Morges, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.

Thierry Fumeaux (T)

Groupement hospitalier de l'ouest lémanique (GHOL), Nyon, Switzerland.

Jérôme Stirnemann (J)

Department of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.

Elise Dupuis Lozeron (E)

Division of Clinical Epidemiology, Geneva University Hospitals, Geneva, Switzerland.

Aimad Ourhamoune (A)

Department of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
Division of Quality of Care, Medical and Quality Directorate, Geneva University Hospitals, Geneva, Switzerland.

Jules Desmeules (J)

Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.

Pierre Chopard (P)

Department of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
Division of Quality of Care, Medical and Quality Directorate, Geneva University Hospitals, Geneva, Switzerland.

Arnaud Perrier (A)

Department of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.

Nicolas Schaad (N)

Pharmacie Interhospitalière de la Côte, Morges, Switzerland.

Pascal Bonnabry (P)

Pharmacy, Geneva University Hospitals, Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH